1-5 of 5
Dipmoy Nath
Close
Sort by
Journal Articles

The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models

Golam Mohi, PhD, Avik Dutta, PhD, Dipmoy Nath, PhD, Yue Yang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4200.
https://doi.org/10.1182/blood-2019-132038
Published: 2019
Journal Articles

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

Dipmoy Nath, PhD, Avik Dutta, MSc, Yue Yang, BS, Clifford Whatcott, PhD, Steven L. Warner, PhD, Golam Mohi, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 54.
https://doi.org/10.1182/blood-2018-99-119421
Published: 2018
Journal Articles

The NF-KB Inhibitor DMAPT in Combination with Ruxolitinib Displays Efficacy in Jak2V617F Knock-in Mouse Model of Myeloproliferative Neoplasms

Yue Yang, BS, Dipmoy Nath, PhD, Avik Dutta, MSc, Peter A Crooks, PhD, Golam Mohi, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1783.
https://doi.org/10.1182/blood-2018-99-120195
Published: 2018
Journal Articles

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm

Yue Yang, Hajime Akada, Dipmoy Nath, Robert E. Hutchison, Golam Mohi
Journal: Blood
Blood (2016) 127 (26): 3410–3423.
https://doi.org/10.1182/blood-2015-11-679431
Published: 2016
Includes: Supplemental data
Journal Articles

Loss of EZH2 Inhibits Erythropoiesis and Accelerates the Development of Myelofibrosis in Jak2V617F Knock-in Mice

Yue Yang, Hajime Akada, PhD, Dipmoy Nath, Robert E Hutchison, MD, Golam Mohi, PhD
Journal: Blood
Blood (2014) 124 (21): 159.
https://doi.org/10.1182/blood.V124.21.159.159
Published: 2014